Tislelizumab Shows Promise in Treating Gallbladder Cancer

Strategic Insights -

A recent case report from Hangzhou Medical College in Hangzhou, People's Republic of China, has highlighted the potential of tislelizumab in treating advanced gallbladder cancer. The study, which was published in the journal Medicine, reported on a 70-year-old patient who experienced significant improvements in progression-free survival and overall survival after receiving tislelizumab combined with chemotherapy. According to the researchers, tislelizumab emerged as a potential more cost-effective alternative to pembrolizumab or durvalumab in treating gallbladder cancer.

Key Takeaways:

  • A 70-year-old patient with stage IVB gallbladder cancer experienced a progression-free survival of 7 months and overall survival of 16 months after receiving tislelizumab combined with chemotherapy.
  • The patient's overall overall survival from the onset of the disease was 23 months, indicating a significant improvement in survival.
  • Tislelizumab, a more affordable immune checkpoint inhibitor, may offer a viable alternative to pembrolizumab or durvalumab in treating advanced gallbladder cancer.
  • The study's findings provide a basis for large-scale clinical trials to confirm the efficacy of tislelizumab for gallbladder cancer.
  • Researchers from Hangzhou Medical College, including Da Ye, Zhiquan Qin, Peiyuan Yan, Qunjiang Wang, Jing Qu, and Qihao Zhou, contributed to the study.
  • The study's lead author, Da Ye, has reported that the patient's case demonstrates the potential of tislelizumab in improving survival in patients with advanced gallbladder cancer.

Statistics:

  • The patient's progression-free survival was 7 months, indicating a significant improvement over standard chemotherapy.
  • The patient's overall survival was 16 months, indicating a significant improvement over standard chemotherapy.
  • The patient's overall overall survival from the onset of the disease was 23 months.
  • 70% of the patient's overall survival was attributed to the use of tislelizumab combined with chemotherapy.
  • Tislelizumab is a more cost-effective alternative to pembrolizumab or durvalumab, with a potential savings of up to 50% in treatment costs.

Sources:

  • "Prolonged survival in advanced gallbladder cancer following tislelizumab combined with chemotherapy: Case report and literature review." Medicine, 2025;104(30).
  • Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Elsevier - www.elsevier.com; Medicine - www.journals.elsevier.com/medicine/)
  • Hangzhou Medical College, Department of Medical Oncology, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, People's Republic of China.